Ranivisio

ranibizumab

Table of contents

Opinion

On 23 June 2022, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Ranivisio, intended for the treatment of neovascular (wet) age-related macular degeneration, visual impairment due to macular oedema or choroidal neovascularisation, and proliferative diabetic retinopathy. The applicant for this medicinal product is Midas Pharma GmbH.

Ranivisio will be available as a 10 mg/ml solution for injection. The active substance of Ranivisio is ranibizumab, a monoclonal antibody fragment (ATC code: S01LA04) which modulates angiogenesis by inhibiting vascular endothelial growth factor A.

Ranivisio is a biosimilar medicinal product. It is highly similar to the reference product Lucentis (ranibizumab), which was authorised in the EU on 22/01/2007. Data show that Ranivisio has comparable quality, safety and efficacy to Lucentis (ranibizumab). More information on biosimilar medicines can be found here.

The full indication is:

Ranivisio is indicated in adults for:

  • The treatment of neovascular (wet) age-related macular degeneration (AMD)
  • The treatment of visual impairment due to diabetic macular oedema (DME)
  • The treatment of proliferative diabetic retinopathy (PDR)
  • The treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO)
  • The treatment of visual impairment due to choroidal neovascularisation (CNV).

Ranivisio must be administered by a qualified ophthalmologist experienced in intravitreal injections.

Detailed recommendations for the use of this product will be described in the summary of product characteristics (SmPC), which will be published in the European public assessment report (EPAR) and made available in all official European Union languages after the marketing authorisation has been granted by the European Commission.

Key facts

Name
Ranivisio
Agency product number
EMEA/H/C/005019
International non-proprietary name (INN) or common name
  • ranibizumab
Active substance
  • ranibizumab
Therapeutic area
Wet Macular Degeneration
Macular Edema
Diabetic Retinopathy
Diabetes Complications
Biosimilar

This is a biosimilar medicine, which is a biological medicine highly similar to another already approved biological medicine called the ‘reference medicine’. For more information, see Biosimilar medicines.

Date opinion adopted
23/06/2022
Company name
Midas Pharma GmbH
Status
Positive
Application type
Initial authorisation

How useful was this page?

Add your rating